Saturday 17 October 2026
Export HBIO’s income statement to Excel — free account
Harvard Bioscience, Inc.
HBIO Healthcare Medical Instruments & Supplies
Harvard Bioscience, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $86.6 million, down 8.06% from fiscal 2024. In the quarter to June 2026, revenue grew 11.1%, EPS fell 28.0%, free cash flow fell 123.4% and total debt rose 5.21%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
8.09
0.22
−2.65%
Follow HBIO
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.32 | 0.25 | 0.34 | 0.22 | |
P/FCF ratio |
0.00 | 17.01 | 6.11 | 2.87 | |
P/Operating CF |
85.65 | (32.91) | (309.81) | 18.09 | |
P/B ratio |
3.75 | 2.17 | 2.17 | 1.39 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1.05 | 0.99 | 1.05 | 0.93 | |
EV/EBITDA |
13.00 | 11.80 | 13.70 | 16.80 | |
EV/Operating CF |
141.29 | 27.54 | 13.52 | 9.47 | |
EV/FCF |
(50.21) | 66.25 | 18.69 | 11.88 | |
Quick Ratio |
0.85 | 0.91 | 1.12 | 0.35 | |
Current Ratio |
1.87 | 1.99 | 2.20 | 0.81 | |
Net Debt/EBITDA |
33.76 | 46.81 | 7.40 | 14.46 | |
Debt/Assets |
48.08% | 46.46% | 44.80% | 43.55% | |
Debt/Equity |
4.95 | 3.60 | 2.61 | 2.41 | |
Asset Turnover |
1.12 | 1.08 | 0.84 | 0.84 | |
Operating CF/Net income |
(0.11) | 0.19 | 0.03 | (0.88) | |
Capex/Depreciation |
(0.49) | (0.35) | (0.30) | (0.21) | |
Interest Coverage |
(0.55) | (0.68) | 0.85 | 0.20 | |
Research and Development Expense of Revenue |
10.79% | 11.21% | 9.20% | 10.35% | |
Selling, General and Administrative Expense of Revenue |
44.08% | 48.36% | 38.81% | 42.68% | |
Intangible Assets out of Total Assets |
0.20 | 0.21 | 0.21 | 0.23 | |
Share Based Compensation of Revenue |
1.67% | 1.24% | 1.93% | 1.57% | |
Graham Net Nets |
(0.80) | (0.94) | (0.61) | (1.03) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(37.56%) | (44.56%) | (191.04%) | (277.27%) | |
Free Cash Flow Yield |
(6.58%) | 5.88% | 16.36% | 34.79% | |
Revenue per Share |
5.02 | 4.64 | 5.35 | 4.62 | |
Operating CF per Share |
0.07 | (0.15) | (0.02) | 0.24 | |
Capex per Share |
(0.20) | (0.14) | (0.13) | (0.08) | |
Free Cash Flow per Share |
(0.13) | (0.29) | (0.16) | 0.17 | |
Cash per Share |
1.44 | 1.59 | 1.94 | 1.53 | |
Shareholders Equity per Share |
1.64 | 2.25 | 3.09 | 3.16 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.64 | 2.25 | 3.09 | 3.16 | |
Free Cash Flow |
(0.59) | (1.28) | (0.69) | 0.74 | |
Working Capital |
21.67 | 23.62 | 26.27 | (10.59) | |
Capital Expenditures |
(0.92) | (0.62) | (0.60) | (0.35) | |
Net Current Asset Value |
(22.40) | (20.41) | (18.11) | (20.12) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.04 | 0.03 | 0.03 | 0.02 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
13.22 | 14.03 | 15.45 | 12.47 | |
Average Payables |
5.47 | 5.05 | 4.22 | 5.23 | |
Average Inventory |
22.24 | 22.51 | 22.03 | 23.80 | |
Average Assets |
78.19 | 78.87 | 103.36 | 104.62 | |
Average Common Equity |
11.58 | 12.44 | 38.54 | 39.70 |
Columns are period end dates